Barclays Increases Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $55.00

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective increased by Barclays from $39.00 to $55.00 in a research report released on Monday, Benzinga reports. The brokerage currently has an overweight rating on the medical device company’s stock.

TNDM has been the topic of several other reports. StockNews.com upgraded shares of Tandem Diabetes Care from a sell rating to a hold rating in a research report on Friday, April 19th. Piper Sandler reissued an overweight rating and issued a $50.00 price target (up from $35.00) on shares of Tandem Diabetes Care in a research note on Friday, May 3rd. Wells Fargo & Company raised Tandem Diabetes Care from an equal weight rating to an overweight rating and boosted their target price for the company from $21.00 to $45.00 in a research report on Monday, April 29th. Citigroup upped their price objective on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a neutral rating in a report on Wednesday, April 3rd. Finally, Robert W. Baird raised their target price on Tandem Diabetes Care from $28.00 to $36.00 and gave the company a neutral rating in a report on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Tandem Diabetes Care has a consensus rating of Moderate Buy and an average price target of $43.80.

Tandem Diabetes Care Stock Up 3.3 %

Shares of NASDAQ:TNDM opened at $45.49 on Monday. Tandem Diabetes Care has a 52-week low of $13.82 and a 52-week high of $47.00. The company has a market capitalization of $2.94 billion, a PE ratio of -20.30 and a beta of 1.10. The company has a debt-to-equity ratio of 1.43, a quick ratio of 3.01 and a current ratio of 3.81. The company has a fifty day moving average of $33.57 and a 200-day moving average of $26.76.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. The firm had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. On average, equities analysts predict that Tandem Diabetes Care will post -1.62 EPS for the current fiscal year.

Institutional Trading of Tandem Diabetes Care

Several hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC raised its holdings in Tandem Diabetes Care by 70.9% during the 3rd quarter. SG Americas Securities LLC now owns 23,510 shares of the medical device company’s stock valued at $488,000 after acquiring an additional 9,751 shares during the period. Commonwealth Equity Services LLC lifted its holdings in Tandem Diabetes Care by 10.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock worth $205,000 after purchasing an additional 908 shares in the last quarter. Raymond James & Associates boosted its stake in Tandem Diabetes Care by 1.9% in the 3rd quarter. Raymond James & Associates now owns 40,264 shares of the medical device company’s stock worth $836,000 after purchasing an additional 737 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Tandem Diabetes Care by 18.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,506 shares of the medical device company’s stock valued at $281,000 after buying an additional 2,103 shares during the period. Finally, Jennison Associates LLC boosted its position in shares of Tandem Diabetes Care by 252.6% in the third quarter. Jennison Associates LLC now owns 1,122,915 shares of the medical device company’s stock valued at $23,323,000 after acquiring an additional 804,488 shares during the period.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.